BB Biotech AG

BION

CH0038389992

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 11:31:30 2024-04-26 am EDT			5-day change	1st Jan Change
40.45 ^CHF	-0.25%		-2.29%	-5.38%

Apr. 26	Switzerland's BB Biotech Swings to Q1 Profit; Operating Income Jumps	MT
Feb. 16	BB Biotech's Loss Narrows in FY23; Operating Income Down	MT

BB Biotech AG authorizes a Buyback Plan.

April 11, 2019 at 12:00 am EDT

The Board of Directors of BB Biotech AG has authorized a buyback plan on April 11, 2019.

Latest news about BB Biotech AG

Switzerland's BB Biotech Swings to Q1 Profit; Operating Income Jumps	Apr. 26	MT
BB Biotech's Loss Narrows in FY23; Operating Income Down	Feb. 16	MT
BB Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
BB Biotech Trims FY23 Dividend as Net Loss Narrows	Jan. 19	MT
BB Biotech Names Successor to Outgoing Chair	Jan. 19	MT
BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-20	CI
Switzerland's BB Biotech Swings to Q3 Loss; Operating Income Shrinks	23-10-20	MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	23-10-20	CI
BB Biotech Shares to be Suspended from Euronext Star Milan Pending Delisting	23-08-21	MT
BB Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-21	CI
Switzerland's BB Biotech to Scrap Listing on Italian Bourse	23-07-21	MT
BB Biotech Logs Decline in H1 Loss, Operating Income	23-07-21	MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	23-07-21	CI
BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-21	CI
Europeans contrasted; gold below USD2,000 threshold	23-04-21	AN
Europeans without momentum ahead of PMIs	23-04-21	AN
BB Biotech Posts Lower Q1 Loss; Operating Income Falls	23-04-21	MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	23-04-21	CI
Europeans down; auto sector suffers	23-04-20	AN
BB Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-17	CI
Swiss Investor BB Biotech's Loss Shrinks in FY22	23-02-17	MT
Tranche Update on BB Biotech AG?s Equity Buyback Plan announced on April 12, 2022.	23-02-17	CI
Mib at more than one-year highs; Tenaris bullish	23-02-16	AN
BB Biotech Proposes Lower FY22 Dividend; Net Loss Narrows	23-01-20	MT
Mib in the red; Alfonsino splashes among PMIs	23-01-19	AN

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companyâs portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.

Sector

Biotechnology & Medical Research

Calendar

2024-07-26 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for BB Biotech AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

40.45 CHF

Average target price

47.7 CHF

Spread / Average Target

+17.92%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BB BIOTECH AG	-5.38%	2.44B
IQVIA HOLDINGS INC.	+1.51%	42.59B
MODERNA, INC.	+8.57%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B

Other Biotechnology & Medical Research

BB Biotech AG

Equities

BION

CH0038389992

Biotechnology & Medical Research

BB Biotech AG authorizes a Buyback Plan.

Latest news about BB Biotech AG

Chart BB Biotech AG

Company Profile

Income Statement Evolution

Ratings for BB Biotech AG

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research